New data adds to X4's hopes on FDA approval in WHIM

A regulatory approval could come within the next year for X4 Pharmaceuticals’ (Nasdaq: XFOR) lead oral CXCR4 antagonist, mavorixafor.

The US company, which is focused on the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, has presented positive top-line results from a pivotal Phase III trial of the drug in WHIM syndrome, which refers to warts, hypogammaglobulinemia, infections and myelokathexis.

"Mavorixafor is the first and only oral investigational therapy to demonstrate durable improvements in severe chronic neutropenia and lymphopenia"